… Therefore, intervening the ADP-ribosylation mediated interplay between PARP1 and viral
proteins may be another important pathway for PARP1 inhibitors to prevent SARS-CoV-2 …

… The resulting endothelialitis can trigger excessive thrombin production in multiple organs
and inhibit fibrinolysis; the complement pathway is also activated, leading to the deposition of …

… repurposing anticancer treatment for the treatment of COVID-19. … inhibitors in patients with
COVID-19 (Table 1). Table 1 Potential drugs with cancer indications for treatment of COVID-19 …

… However, blockage of JAK-STAT pathway leads to inhibition of IFN production which may
cause impairment of anti-viral immunity [25]. Currently, 20 clinical trials are ongoing for …

… suggests that PDE5 inhibitors could offer a new strategy in managing COVID-19 by (i) … -to-severe
symptoms of COVID-19 may offer a therapeutic benefit by targeting inflammation and …

… Therefore, MLN-4760 might be helpful not only for COVID-19 but also in targeted therapies
for pathologies correlated with an excessive increase of ACE2 activity that may involve heart, …

… interest for the treatment of COVID-19. Lopinavir is a protease inhibitor with high specificity
for … Since tocilizumab seems able to prevent the hyperactivation of inflammatory pathway, its …

… inhibitors vg CyA exert and inhibitory effect on SARS-CoV through the calcineurin pathway
inhibition … /Nuclear Factor of activated-T cells inflammatory pathway induced by SARS- [46,47]…

… and S1PR 1 are observed in postmyocardial infarction (MI) associated with the proinflammatory
response, and inhibition of this inflammatory pathway may benefit patients with MI [263]. …

… JAK/STAT signal pathway and its inhibitor. Cytokines and growth … inhibition of inflammation
by IL-6, IFN-γ and GM-CSF, indicating its usefulness as a therapeutic agent for Covid-19 …